SRC plays a multifaceted oncogenic role in CCA by activating key signaling pathways, interacting with FAK in response to HGF to promote proliferation and invasion, forming a metastatic SRC–Hic-5–AKT cascade, and phosphorylating YAP to drive tumor growth and therapy resistance [53]. Here, PTK2 is linked to cholangiocarcinoma.